J. Craig Venter Institute Announces Management Team and Organizational Structure
News Apr 13, 2007
The J. Craig Venter Institute (JCVI), formed in October 2006 through the merger of several affiliated organizations—The Institute for Genomic Research (TIGR), The Center for the Advancement of Genomics (TCAG), and the J. Craig Venter Science Foundation (JCVSF), has announced the new management team and organizational structure for the JCVI.
J. Craig Venter, Ph.D., founder, remains as Chairman and President of the new JCVI. Robert Strausberg, Ph.D., who had been president of the TCAG division, is now the Deputy Director. Marv Frazier, Ph.D., former Vice President for Research at TCAG is now the Executive Vice President for Research.
The General Counsel for the JCVI is Julie Gross Adelson; Chief Financial Officer is Aimee Turner, who was formerly CFO at TIGR; Vice President of Human Resources is Robin Hoesch and Robert Friedman remains as Vice President for Public Policy.
The Institute will no longer be organized under the two research divisions TIGR and TCAG, but will now encompass an administrative team and the following research groups: Genomic Medicine, Infectious Disease, Synthetic Biology & Bioenergy, Plant Genomics, Microbial & Environmental Genomics, Pathogen Functional Genomics Resource Center (PFGRC), Applied Bioinformatics, Research Informatics, Software Engineering, and the Policy Center.
The genomic sequencing capability remains a cornerstone of activities at the JCVI and will continue to be led by Yu-Hui Rogers. Eric Eisenstadt, former Vice President for Research of TIGR is the new Deputy Vice President for Research.
With six buildings and more than 250,000 square feet of lab space in Rockville, MD, as well as a research facility in La Jolla, CA, and combined assets of more than $200 million, JCVI is one of the largest independent research institutes in the Unites States. There are approximately 500 employees, of whom nearly 400 are dedicated to research with 124 of those having doctoral degrees.
The organization also boasts one Nobel Laureate and three members of the National Academy of Sciences.
“Since the earliest days of founding TIGR in 1992 and then with the other affiliated institutes, my goal has always been to create unique and dynamic research organizations that push the boundaries of traditional science. We have long been leaders in genomics and with our newly organized Institute, I am certain we are poised to continue to blaze new trails in this field,” said Dr. Venter.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.